OPKO Health (NASDAQ:OPK) Issues Quarterly Earnings Results

OPKO Health (NASDAQ:OPK) announced its quarterly earnings data on Wednesday. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the consensus estimate of ($0.07), FiscalAI reports. The company had revenue of $130.83 million during the quarter, compared to analyst estimates of $136.62 million. OPKO Health had a negative net margin of 29.51% and a negative return on equity of 10.66%. The firm’s revenue for the quarter was down 56.9% compared to the same quarter last year. During the same period last year, the business earned $0.03 EPS.

Here are the key takeaways from OPKO Health’s conference call:

• OPKO agreed to sell substantially all of BioReference’s remaining operations to Labcorp for about $722 million in cash, with potential 4Kscore royalties of up to $150 million over 10 years. The deal, which remains subject to customary closing conditions, would complete OPKO’s exit from diagnostics and refocus it on biotech and global products.
• Continuing-operations revenue rose 16% to $65.4 million year over year, led by OPKO Iberoamerica, RAYALDEE and mazdutide royalties. Global products reported $6 million of operating income, versus a $1.2 million loss a year earlier.
• Pipeline programs advanced, including completion of enrollment in the planned phase I cohorts for MDX-2301, with management describing its blinded safety profile as favorable. OPKO is preparing subcutaneous dosing studies for several ModeX candidates, while its first in vivo CAR-T program is now targeted for first-in-human studies in mid-2027, later than previously planned.
• Innovative biotech’s operating loss widened to $26.8 million from $22.5 million, as increased research and development activity raised costs. OPKO expects about $125 million in BioReference sale-related costs, and forecast a roughly $40 million loss from discontinued operations in Q4.
• OPKO ended the quarter with $403.2 million in cash, cash equivalents and restricted cash, and repurchased 7.2 million shares for $10.6 million. It withdrew consolidated full-year guidance and issued continuing-operations revenue guidance of $268 million–$278 million; management said it would provide more detail on capital allocation as the Labcorp closing approaches.

OPKO Health Stock Performance

Shares of NASDAQ:OPK traded up $0.03 during trading on Friday, reaching $1.77. 3,661,765 shares of the company’s stock traded hands, compared to its average volume of 3,245,827. The stock has a market capitalization of $1.32 billion, a P/E ratio of -9.39 and a beta of 1.52. OPKO Health has a 12 month low of $0.98 and a 12 month high of $1.86. The company has a 50 day moving average of $1.58 and a 200-day moving average of $1.35. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.35 and a quick ratio of 2.93.

Analyst Ratings Changes

A number of research firms have commented on OPK. UBS Group set a $4.00 target price on OPKO Health in a report on Friday, October 16th. HC Wainwright reiterated a “buy” rating on shares of OPKO Health in a research report on Friday, October 16th. Zacks Research upgraded OPKO Health from a “hold” rating to a “strong-buy” rating in a report on Monday, September 28th. Barrington Research raised OPKO Health from a “market perform” rating to an “outperform” rating and set a $2.25 price target on the stock in a research report on Friday, October 16th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a research report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $3.42.

More OPKO Health News

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: OPKO agreed to sell substantially all of its remaining BioReference diagnostic operations to Labcorp for $722 million in cash. The proceeds give the company significant funding as it narrows its focus to biotech. OPKO Q3 results and business highlights
• Positive Sentiment: OPKO forecast 2026 revenue from continuing operations of $268 million to $278 million following the planned sale, providing investors a view of the expected business after the divestiture. 2026 continuing-operations revenue outlook
• Neutral Sentiment: Third-quarter results showed a loss of $0.05 per share, better than Zacks’ consensus loss estimate of $0.07, while reported revenue of $65.4 million fell well short of the roughly $136.6 million estimate. The revenue shortfall may weigh on sentiment, though comparisons are affected by the planned diagnostics divestiture. Q3 earnings report
• Negative Sentiment: Reports from the earnings call said biotech losses widened and the CAR-T program timeline was delayed, raising concerns about continuing cash needs and the timing of potential pipeline progress. Q3 earnings call transcript
• Negative Sentiment: Director John A. Paganelli reported selling shares on November 5. He retained approximately 390,000 shares, so the sales were limited relative to his remaining holding, but insider selling can still be a modest sentiment headwind. SEC insider transaction filing

OPKO Health Company Profile

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its BioReference Laboratories business, the company provides clinical laboratory services, including routine testing, specialty diagnostics, genetic testing and oncology-related laboratory services. OPKO also develops diagnostic products, including the 4Kscore test, a blood test designed to help assess the risk of aggressive prostate cancer.

In pharmaceuticals, OPKO develops treatments for kidney disease, endocrine disorders and other conditions.